- InMed Pharmaceuticals ( NM ) will be consolidating al l of its issued and outstanding share capital on the basis of one for each twenty five pre?consolidation shares in order to regain compliance with all of Nasdaq’s continued listing requirements.
- Company shares being reduced from ~18M to ~720k common shares on a non-diluted basis.
- Shares will begin trading on a split-adjusted basis on the Nasdaq commencing at the market open, September 7, 2022.
- Stock dips 16% during after market hours.
For further details see:
InMed Pharmaceuticals sinks 16% over consolidating 1 for 25 shares to meet listing requirements